1. Min BS, Kim NK, Ahn JB, Roh JK, Kim KS, Choi JS, Cha SH, Kim H. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastasis. Onkologie 2007;30: 637–43.
2. Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with cetuximab/FOLFOX-4 in the treatment of mCRC epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol. 2006;17:450–6.
3. Peeters M, Raoul JL, van Laethem JL, Rougier P, Brezault C, Husseini F, Cals L, Zubel A, Vedovato JC. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC). Eur J Cancer (Suppl). 2005;3:188.
4. van Cutsem E, Nowacki M, Lang I. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Slides presented at ASCO 2007 annual meeting, Chicago, 15 Jun 2007. Abstract 4000.
5. Tabernero J, van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, van Laethem JL, Soulié P, Casado E, Verslype C, Sastre J, Tortora G, Ciardiello F, Kisker O, de Gramont A. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007;33:5225–32.